

A PRIMARY CARE GUIDE TO KEY CLINICAL QUESTIONS IN OSTEOPOROSIS MANAGEMENT

This interactive program has been specifically designed to address the most frequently encountered clinical challenges in the management of patients with osteoporosis or at risk for osteoporotic fracture in the primary care setting. This activity was developed by leading Canadian Experts to provide clinicians with answers to frequently asked questions and key take-away messages that can be applied to real-world practice.



Evaluation Form

DATE

LOCATION

location name 117 silver linden
dr

Demographics

Physician: ☐ Yes ☐ No ☐ Other ☐ Please specify _____

Type of Practice: ☐ Full-time ☐ Part-time ☐ Solo ☐ Group ☐ Office ☐ Hospital ☐ Other

Speaker: testingspk1, testingspk1

Was effective in Presenting Material:

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

Moderator: asfd, safd

Was effective in Presenting Material:

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

Did you perceive any degree of bias in any part of the program?

☐ Yes

☐ No

If so, please explain: _____

LEARNING OBJECTIVES: What parameters indicate a diagnosis of osteoporosis? How does this differ from assessment of fracture risk?

After participating in this activity, I am now better able to:

1. Perform risk assessments and screening for all patients at high risk for fracture

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Explain the factors that determine osteoporotic fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: How can we best explain the impact of osteoporosis to our patients?

After participating in this activity, I am now better able to:

1. Describe the morbidity, mortality and economic burden of illness associated with osteoporosis in Canada

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Explain the factors that determine osteoporotic fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Communicate to patients the impact of osteoporotic fractures on their quality of life and the actions they can take to reduce risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: How do we evaluate fracture risk in postmenopausal women with a view to identifying women who would benefit from osteoporosis pharmacotherapy?

After participating in this activity, I am now better able to:

1. Identify clinical and diagnostic risk factors which further increase the risk of fractures in post menopausal women

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Apply evidence-based management protocols to prevent future fractures in post menopausal women

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Assess patients on treatment for occurrence of side effects and select appropriate therapies based on the patient characteristics

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: How do we evaluate fracture risk in older men, and what are the therapeutic options?

After participating in this activity, I am now better able to:

1. Identify social, clinical and diagnostic risk factors which further increase the risk of fractures specific to male patients

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Apply evidence-based management protocols to prevent future fractures in male patients

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Assess patients on treatment for occurrence of side effects and select appropriate therapies based on the patient characteristics

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Do patients on glucocorticoid require osteoporosis pharmacotherapy?

After participating in this activity, I am now better able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe why glucocorticoid treatment is associated with bone loss and increased fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: What is the risk of fracture in patients on aromatase inhibitor therapy?

After participating in this activity, I am now better able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe why aromatase inhibitor therapy is associated with bone loss and increased fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Do patients on androgen deprivation therapy require osteoporosis pharmacotherapy?

After participating in this activity, I am now better able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe why patients on androgen deprivation therapy are at risk for bone loss and will benefit from pharmacotherapy to prevent osteoporotic fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Do proton pump inhibitors cause bone loss?

After participating in this activity, I am now better able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe why treatment with proton pump inhibitors may be associated with bone loss and increased fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: When patients are treated with Selective Serotonin Receptor Inhibitors, do they have an increase in the risk of fracture?

After participating in this activity, I am now better able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe why chronic SSRI treatment is associated with increased fragility fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: How long do osteoporosis patients need to be treated?

After participating in this activity, I am now better able to:

1. Incorporate the history of prior fractures in determining future risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Assess the risk of falls as a major and independent risk for fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Consider patient preference when selecting long term treatment

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

4. Explain the importance of adherence including avoidance of drug holidays in high risk individuals

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

This Program

Content enhanced my knowledge

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Addressed my most pressing questions

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Promoted improvements or quality in health care

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Was scientifically rigorous and evidence-based

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Provided appropriate and effective opportunities for active learning

(ie., case studies, discussion, Q &A, etc)

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Provided an opportunity for interaction with my peers

Strongly disagree Neutral Strongly agree

1 2 3 4 5

Please indicate with CAnMEDS roles you felt were addressed during this educational activity.

- ☐ Family Medicine Expert
- ☐ Collaborator
- ☐ Communicator
- ☐ Manager
- ☐ Health Advocate
- ☐ Professional
- ☐ Scholar

Based on your participation in this program, please select all applicable statement(s):

- ☐ I gained new strategies/skills/information that I can apply to my area of practice.
- ☐ I plan to implement new strategies/skills/information into my practice.
- ☐ I need more information before I can implement new strategies/skills/information into my practice behavior
- ☐ This program will not change my practice, as my current practice is consistent with the information presented.
- ☐ This program will not change my practice, as I do not agree with the information presented.

What strategies/changes do you plan to implement into your practice?

What barriers do you see to making a change in your practice?

Future Topics of Interest / Additional Comment & Suggestions

Thank you for your feedback!